Products
We have two treatments, approved in the U.S. and Europe, based on a unique mechanism of action that represent an important step forward in cardiovascular disease management. By partnering with commercial organizations, we’re working to enable broad access to our medicines globally.
Pipeline
Our scientific team is leading the investigation of ACLY biology having brought the first ACLY inhibitor to the market. Along with the implementation of leading-edge discovery technology and data science approaches, we aim to reveal new therapeutic opportunities and develop next-generation inhibitors optimized to address multiple life-threatening diseases.
